AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026, 12:01 PM ET H.C. Wainwright maintains $22 price target on Vir Biotechnology AI-generated summary · Source: press report
$VIRHealthcareClinical evidenceExecution and funding risk

VIR Stock Hub: Vir Biotechnology News, ECLIPSE and Oncology

On November 8 Vir reported that the Phase 3 ECLIPSE 1 hepatitis-delta trial met its primary endpoint; it is also expanding its masked T-cell-engager oncology portfolio. Cash, cash equivalents and investments were approximately $901.3 million at September 30, before $90 million received from Gilead in October; the company still guides funding into the second half of 2028. The results were presented at AASLD on November 8; the company hosted an investor call on November 9 at 8:30 a.m. ET.

Last updated: November 9, 2026Market reference: November 4, 2026 regular-session closeFinancial period: September 30, 2026Currency: U.S. dollars unless stated
Full research report · PDF
Vir Biotechnology ($VIR), research updated November 5, 2026
21 pages · Third-quarter 2026 results and corporate update: about $901.3 million of cash, equivalents and investments at September 30, quarterly cash use, the $90 million Gilead receipt, share count, the Q4 2026 ECLIPSE 1 window and VIR-5500 plans, plus the SOLSTICE evidence, ECLIPSE 1, 2 and 3, PRO-XTEN oncology, partner economics, price chart to the November 4 close and Health Score. For personal use only: redistribution prohibited.
Get the report (PDF)
Next announced event
November 18, 2026 · Jefferies London fireside chat · Q1 2027 · ECLIPSE 2 and ECLIPSE 3 topline

On November 8 Vir announced that the Phase 3 ECLIPSE 1 trial of elebsiran plus tobevibart in chronic hepatitis delta met its primary endpoint: 44% of treated patients achieved undetectable HDV RNA plus ALT normalization at Week 48, versus 0% in the delayed treatment group at Week 12 (p<0.0001). The results were presented in an oral session at AASLD The Liver Meeting 2026 in Denver. Vir hosted a conference call on the ECLIPSE 1 topline results on Monday, November 9 at 8:30 a.m. ET; a U.S. FDA submission is planned for mid-2027. Company release

Third-quarter results were reported November 4. ECLIPSE 2 and ECLIPSE 3 topline remain guided to Q1 2027.
Vir Biotechnology VIR daily stock chart
Daily chart $VIR. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

VIR stock at a glance

Close · November 4, 2026
$11.77
Regular-session close; +4.90% versus $11.22 on November 3. Q3 results were released after the close.
Equity value · dated common shares
~$2015.9M
Calculated with the November 4 close and 171,270,773 common shares at October 28, 2026 (Merlintrader calculation); later changes excluded.
Cash and equivalents
$218.866M
September 30, 2026 · Source
Short-term investments
$235.769M
September 30, 2026 · Source
Long-term investments
$442.932M
September 30, 2026 · Source
Common shares
171.271M
October 28, 2026 · rounded · Source
9M operating cash use
$115.141M
Nine months to September 30; $9.060M in H1, which included collaboration cash · Source
Funding guidance
H2 2028
Company operating plan · reiterated November 4, 2026 · Source

Where Vir Biotechnology stands now

Vir Biotechnology is a San Francisco-based clinical-stage biotechnology company working in infectious diseases and oncology. Its nearer-term clinical program is the combination of elebsiran and tobevibart for chronic hepatitis delta. Its oncology portfolio comprises the PSMA-targeted VIR-5500, HER2-targeted VIR-5818 and EGFR-targeted VIR-5525, together with preclinical discovery programs built around the PRO-XTEN masking technology. The common theme is immune-directed medicine, but the clinical maturity, financial arrangements and commercial responsibilities differ substantially across these programs. The central distinction is between a hepatitis-delta program with a first positive Phase 3 readout and an expanding early-stage oncology platform. On November 8, 2026, Vir reported that ECLIPSE 1 met its primary endpoint, with results presented at AASLD, and hosted an investor call on November 9; ECLIPSE 2 and ECLIPSE 3 data are expected in the first quarter of 2027 and a U.S. FDA submission is planned for mid-2027. VIR-5500 remains in Phase 1, with pivotal studies anticipated in 2027. The Gilead collaboration announced on October 14 concerns the discovery and engineering of three new development candidates, not three approved products or three completed clinical programs. Each part therefore belongs at a different point in the development and valuation chain.

On November 4, 2026, Vir reported approximately $901.3 million of cash, cash equivalents and investments at September 30, a decrease of $106.5 million during the third quarter, and a quarterly net loss of $96.3 million, or $0.57 per share, against $163.1 million a year earlier. The $90 million of Gilead consideration, a $65 million upfront payment and a $25 million equity investment, was received after quarter-end. The company continues to expect its cash, cash equivalents and investments to fund operations into the second half of 2028. It also plans a virtual research investor event on its oncology strategy in the first quarter of 2027. Q3 2026 corporate update · Q3 Form 10-Q

Different programs, different evidence clocks. ECLIPSE 1 met its primary endpoint, but ECLIPSE 2 and ECLIPSE 3 outcomes remain pending, while oncology evidence is early and partner economics are conditional. A profitable quarter or low reported operating cash use can reflect collaboration receipts rather than recurring product economics.

The constructive case

Vir has financial resources and multiple clinical opportunities. The elebsiran–tobevibart combination achieved HDV RNA target not detected in 28 of 32 participants at Week 96 in the SOLSTICE intent-to-treat analysis. In the controlled ECLIPSE 1 trial, reported November 8, 2026, the combination met its primary endpoint; ECLIPSE 2 and ECLIPSE 3 data are expected in Q1 2027. The same day Vir reported that all 28 SOLSTICE participants who completed Week 96 of combination therapy had undetectable virus; in a separate exploratory analysis, all 10 patients who stopped treatment after at least 96 weeks of undetectable virus achieved SVR12 (7 SVR24, 1 SVR48), with follow-up of 12 to 48 weeks. A November 9 Form 8-K calls this finite-treatment analysis exploratory and based on interim data without a formal data cut, with follow-up for possible delayed liver flares still ongoing. Form 8-K SOLSTICE release Astellas participates in clinical-stage VIR-5500; Gilead’s newer agreement funds discovery of additional candidates. A favorable outcome would combine reproducible clinical results with disciplined use of the capital and capabilities available.

The cautious case

ECLIPSE 2 and ECLIPSE 3 results, FDA review and commercial execution remain ahead, and each program faces a different risk. In ECLIPSE 1 the combined viral-and-biochemical primary endpoint was reached by 44% of treated patients, against 79% for undetectable virus alone, and the comparison was with delayed treatment at Week 12 rather than with an active drug. Early oncology response rates come from small evaluable subsets. HDV already has an FDA-approved competitor, and Vir keeps significant development spending and licensing obligations. An adverse clinical result or higher spending could reduce the flexibility provided by its balance sheet.

Latest Vir Biotechnology news

Nov 9, 2026

H.C. Wainwright maintains $22 price target on Vir Biotechnology

H.C. Wainwright kept its price target on Vir Biotechnology at $22. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 9, 2026

Vir reports 10 patients achieved SVR12 after stopping elebsiran and tobevibart in SOLSTICE

Vir Biotechnology's exploratory analysis of the Phase 2 SOLSTICE study found that all 10 patients who discontinued elebsiran and tobevibart treatment achieved SVR12. Seven of these patients reached SVR24 and one reached SVR48. The 10 patients, 7 of whom are cirrhotic, chose to discontinue after maintaining undetectable virus for at least 96 weeks, with follow-up ranging from 12 to 48 weeks. All 10 maintained stable ALT with no viral rebound or ALT flares, though the interim data are preliminary and not formally cut.

Nov 8, 2026

Bank of America lifts Vir Biotechnology price target to $17 from $15

Bank of America raised its price target on Vir Biotechnology to $17 from $15 and kept a Buy rating. The company recently announced that the Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in chronic hepatitis delta met its primary endpoint, with a 44% response rate at Week 48 versus 0% in the delayed treatment group at Week 12. The key secondary endpoint was also met. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 8, 2026

Expanded Phase 2 SOLSTICE data for elebsiran and tobevibart in chronic hepatitis delta

Vir Biotechnology announced expanded Phase 2 SOLSTICE data for elebsiran and tobevibart in chronic hepatitis delta. The data show deep and sustained viral suppression, and exploratory finite treatment data were also reported.

Nov 8, 2026

Vir Biotechnology announces primary endpoint met in ECLIPSE 1 hepatitis delta trial

Vir Biotechnology announced that the primary endpoint was met in the pivotal Phase 3 ECLIPSE 1 trial. The trial concerns elebsiran and tobevibart in chronic hepatitis delta.

Nov 5, 2026

Vir Biotechnology to present Phase 3 ECLIPSE 1 data in chronic hepatitis delta

Vir Biotechnology will present topline Phase 3 ECLIPSE 1 data for elebsiran and tobevibart in chronic hepatitis delta at AASLDs The Liver Meeting 2026. The company will also host an investor conference call.

VIR stock catalysts: development and reporting dates

  • November 4, 2026 — Third-quarter results and corporate update reported; conference call at 4:30 p.m. ET. Completed
  • November 7, 2026 · 5:45 p.m. MT — SOLSTICE translational sub-study on intrahepatic NK cells, oral presentation at AASLD The Liver Meeting (Denver). Completed
  • November 8, 2026 · 2:15 p.m. MT — ECLIPSE 1 Phase 3 met its primary endpoint: 44% of patients on elebsiran plus tobevibart achieved undetectable HDV RNA plus ALT normalization at Week 48, versus 0% with delayed treatment at Week 12; topline results were presented in an oral session at AASLD. Expanded Phase 2 SOLSTICE data were also presented (28 of 28 participants with undetectable virus at Week 96). Completed · company release SOLSTICE release
  • November 9, 2026 · 8:30 a.m. ET — Investor conference call and webcast on ECLIPSE 1 topline and expanded SOLSTICE data. Held
  • November 18, 2026 — President and CEO Marianne De Backer presents in a fireside chat at the Jefferies 2026 London Healthcare Conference, 10:30 a.m. GMT / 5:30 a.m. ET; live webcast on the investor site, archived for 30 days. An investor presentation is not a data release. Company-announced investor event
  • Q1 2027 — ECLIPSE 2 and Phase 2b ECLIPSE 3 topline. Separate company targets
  • Q1 2027 — Virtual research investor event on the oncology strategy and new preclinical candidates. Company plan
  • Mid-2027 — Planned U.S. FDA submission of a global regulatory filing package for elebsiran and tobevibart, supported by data from all three ECLIPSE trials. Company plan
  • 2027 — Start of multiple VIR-5500 pivotal trials, with Astellas. Company expectation

November 8, 2026 ECLIPSE 1 topline results · November 8, 2026 ECLIPSE 1 results · November 5, 2026 AASLD presentations and conference call · November 4, 2026 corporate update and Q3 results · June quarterly financials · Jefferies London conference announcement

ECLIPSE: separate hepatitis-delta questions

ECLIPSE 1 is the Phase 3 study behind Vir’s fourth-quarter 2026 readout: on November 8, 2026, Vir reported that it met its primary endpoint. The company describes it as an evaluation of elebsiran plus tobevibart against deferred treatment in the United States or other regions where bulevirtide use is limited. By the August 5 update, Vir reported that the entire ECLIPSE registrational program was fully enrolled. The trial is registered as NCT06903338. On November 5, 2026, Vir said it would present the ECLIPSE 1 primary endpoint results in a late-breaking oral presentation at AASLD The Liver Meeting on November 8 and discuss them on a conference call on November 9. On November 8 it reported that ECLIPSE 1 met its primary endpoint. The trial enrolled 124 patients, randomized 2:1, including patients with advanced disease; the delayed-treatment group started therapy at Week 12. Undetectable virus plus ALT normalization was reached by 44% of the 83 treated patients at Week 48, against 0% of the 41 delayed-treatment patients at Week 12 (p<0.0001). Undetectable virus alone was reached by 79% (85% of 46 cirrhotic and 73% of 37 non-cirrhotic patients), virologic response by 100%, ALT normalization by 53% versus 5%, and HBsAg below 10 IU/mL, an exploratory measure, by 95%. The company reported one Grade 3 treatment-related adverse event, a decrease in neutrophil count that resolved in 15 days, no treatment interruptions or discontinuations, and flu-like symptoms, mostly at the first dose, as the most common treatment-related event. The combination holds FDA Breakthrough Therapy and Fast Track designations and EMA PRIME and orphan designations; it remains investigational, and a U.S. FDA submission is planned for mid-2027. Company release · November 8 results

ECLIPSE 3 is a Phase 2b head-to-head trial of elebsiran plus tobevibart against bulevirtide in bulevirtide-naïve patients. Vir describes it as supportive evidence intended to inform access and reimbursement in important markets. Its place within a registrational program does not change its phase: ECLIPSE 1 and ECLIPSE 2 are Phase 3 studies, whereas ECLIPSE 3 is Phase 2b. The registry, NCT07142811, lists Phase 2.

Vir cash and collaboration economics

At June 30, 2026, cash and cash equivalents were $278.729 million, short-term investments $249.864 million and long-term investments $475.016 million. Their calculated sum is $1,003.609 million. The balance sheet separately lists $4.133 million of equity investments. Including that separate line produces $1,007.742 million, consistent with the company’s rounded description of approximately $1.01 billion in cash, equivalents and investments.

Vir reported $9.060 million of net cash used in operating activities for the first six months of 2026, compared with $198.335 million in the corresponding 2025 period. The 2026 number includes the $240 million Astellas upfront receipt and the $48 million Sanofi payment. It is therefore not a clean measure of what ordinary development activity consumes in a period without a major collaboration transaction.

At September 30, 2026, cash and cash equivalents were $218.866 million, short-term investments $235.769 million and long-term investments $442.932 million, with a further $3.722 million of equity investments: about $901.3 million in total, as reported by the company. Operating activities used $115.141 million in the first nine months of 2026, which implies a calculated $106.081 million in the third quarter alone. In October Vir received $90.0 million from Gilead, a $65.0 million upfront payment and a $25.0 million purchase of 1,765,486 shares at $14.16, which is not included in the September 30 balance. Q3 Form 10-Q

Merlintrader Health Score · $VIR

3.35out of 5
Financial resources · 30%4.0

About $901.3 million of cash, equivalents and investments at September 30, 2026, down $106.5 million in the quarter, plus $90.0 million of Gilead consideration received in October, with no debt and funding guided into H2 2028. The score moves from 4.5 to 4.0 because quarterly cash use near $106 million, without large collaboration receipts, now sets the pace of the runway. Source Source

Catalysts · 30%3.5

ECLIPSE 1 met its primary endpoint, as reported on November 8 (44% versus 0%, p<0.0001), with an investor call held on November 9; ECLIPSE 2 and 3 data are expected in Q1 2027, a U.S. FDA submission is planned for mid-2027 and oncology evidence remains early. The score moves from 3.0 to 3.5 after the positive pivotal readout. Source

Capital allocation · 20%2.5

Partners distribute costs and economics; Vir keeps program commitments, contractual payments and dilution exposure.

Trading liquidity · 10%3.0

Nasdaq-listed common stock with 171,270,773 shares outstanding at October 28, 2026. Event-driven gaps around the ECLIPSE readouts can still overwhelm ordinary session liquidity. Source

Operating execution · 10%3.0

ECLIPSE 1 reported positive topline results, with all patients completing 48 weeks of treatment, and VIR-5500 expansion has advanced; ECLIPSE 2 and 3 outcomes, the regulatory filing and commercial execution remain ahead.

Reassessed November 8, 2026 after the ECLIPSE 1 topline results: Catalysts moves from 3.0 to 3.5, other scores unchanged. Reviewed November 9, 2026 after the investor call and the November 9 Form 8-K: scores unchanged. Weighted calculation: 4.0×30% + 3.5×30% + 2.5×20% + 3.0×10% + 3.0×10% = 3.35. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

  • ECLIPSE 1 met its primary endpoint, but ECLIPSE 2 and ECLIPSE 3 outcomes remain pending, while oncology evidence is early and partner economics are conditional. A profitable quarter or low reported operating cash use can reflect collaboration receipts rather than recurring product economics.
  • ECLIPSE 2 and ECLIPSE 3 results, FDA review and commercial execution remain ahead, and each program faces a different risk. In ECLIPSE 1 the combined viral-and-biochemical primary endpoint was reached by 44% of treated patients, against 79% for undetectable virus alone, and the comparison was with delayed treatment at Week 12 rather than with an active drug. Early oncology response rates come from small evaluable subsets. HDV already has an FDA-approved competitor, and Vir keeps significant development spending and licensing obligations. An adverse clinical result or higher spending could reduce the flexibility provided by its balance sheet.

VIR Stock FAQ: Vir Biotechnology Questions Answered

What is the next catalyst for VIR stock?

As of November 9, 2026, Vir’s next dated event is the CEO’s fireside chat at the Jefferies 2026 London Healthcare Conference on November 18; the company hosted an investor call on the ECLIPSE 1 results on November 9 at 8:30 a.m. ET. On November 8 Vir reported that Phase 3 ECLIPSE 1 met its primary endpoint: 44% of patients on elebsiran plus tobevibart achieved undetectable HDV RNA plus ALT normalization at Week 48, versus 0% with delayed treatment at Week 12 (p<0.0001). ECLIPSE 2 and ECLIPSE 3 data are expected in Q1 2027; a U.S. FDA submission is planned for mid-2027. November 8 ECLIPSE 1 results. November 18 Jefferies presentation.

Are Vir’s hepatitis-delta drugs FDA approved?

No. Positive Phase 3 data are not an approval: in its November 8, 2026 ECLIPSE 1 announcement Vir describes elebsiran and tobevibart as investigational agents and plans a U.S. FDA submission in mid-2027; the combination holds FDA Breakthrough Therapy and Fast Track designations. ECLIPSE 1 results and filing plan. Separately, VIR-5500 received FDA Fast Track designation for metastatic castration-resistant prostate cancer on October 8. Fast Track supports development and review; VIR-5500 remains an investigational Phase 1 therapy. Investigational hepatitis-delta combination. VIR-5500 Fast Track and clinical status.

How much cash does Vir have and how long could it last?

Vir reported approximately $901.3 million in cash, cash equivalents and investments at September 30, 2026: $218.866 million cash and equivalents, $235.769 million short-term investments, $442.932 million long-term investments and $3.722 million equity investments. Operating activities used $115.141 million in the first nine months; the first half had been affected by a $240 million Astellas upfront receipt and a $48 million payment to Sanofi. The $90 million received from Gilead in October is not in that balance. On November 4 the company reiterated that it expects these resources to fund operations into the second half of 2028. September 2026 financial statements and cash flows. November 4 funding guidance.

Could VIR shareholders face more dilution?

Yes. Vir had 171,270,773 common shares outstanding on October 28, 2026, against 139,474,954 at December 31, 2025, after a February public offering of 20,294,117 shares and the issuance of 7,239,382 shares to Astellas in connection with the collaboration agreement. Under the Gilead agreement, Gilead bought 1,765,486 shares at $14.16 in October. The Q3 filing reports no sales through September 30 under the $300 million ATM program and states that the agreement expired in November 2026. Q3 Form 10-Q, common shares and financing. October 14 Gilead agreement.

When will Vir report its next earnings?

Vir reported its Q3 2026 financial results and corporate update on November 4, 2026, with a conference call at 4:30 p.m. Eastern time. As of that date, it had not announced the date of its next quarterly report. Q3 2026 results.

What does Vir Biotechnology do?

Vir develops immune-directed treatments for serious infectious diseases and cancer, as described in its October 21, 2026 announcement. Its clinical pipeline includes elebsiran plus tobevibart for chronic hepatitis delta and PRO-XTEN dual-masked T-cell engagers for solid tumors. The oncology candidates are at earlier stages than the hepatitis-delta registrational program. Vir business and pipeline. Clinical development stages.

Are all three Vir ECLIPSE trials Phase 3?

No. Vir’s August 5, 2026 update identifies ECLIPSE 1 and ECLIPSE 2 as Phase 3 studies, while ECLIPSE 3 is Phase 2b. ECLIPSE 1 compares the combination with deferred treatment; ECLIPSE 2 evaluates switching from bulevirtide in patients without viral suppression. ECLIPSE 3 compares the combination directly with bulevirtide in bulevirtide-naïve patients. ECLIPSE study phases and populations.

Does Vir’s Gilead deal include VIR-5500?

No. Vir’s October 14, 2026 Gilead agreement concerns discovery and engineering of three new PRO-XTEN T-cell-engager development candidates. Astellas is the development and commercialization partner for clinical-stage VIR-5500. The Gilead discovery programs and the existing VIR-5500 program therefore have different partners, development stages and economics. Gilead discovery collaboration. Astellas partnership for VIR-5500.

Primary sources

This blog content is provided for informational and educational purposes only. It is not investment advice.

Disclaimer. Merlintrader publishes educational and informational content, not investment advice, a recommendation, or an offer to buy or sell securities. Company guidance and editorial scenarios are uncertain. Readers should conduct their own research and consult a licensed financial adviser when appropriate.

Biotechnology development carries clinical, regulatory, manufacturing, commercial and financing risks. Preliminary results may change; partnership milestones are conditional; further share issuance can dilute ownership. Trading can cause partial or total loss of capital.

Merlintrader may hold positions in securities discussed. Some links, including Finviz links, are affiliate links and may generate compensation at no additional cost to the reader. See the disclaimer and terms of use and privacy.